Qrons

Company Overview

Snapshot

Founded in January 2016 by Jonah Meer and Ido Merfeld, Qrons operates with 1–10 employees. The company has raised $500K across two funding rounds and went public on OTC in August 2017.

Business overview

Qrons is a biotechnology company focused on developing advanced biotech products, treatments, and technologies to combat neuronal diseases. The company leverages artificial intelligence, machine learning, molecular biology, stem cells, and tissue engineering to create its solutions. Its core product candidates, QS100 and QS200, are designed to treat traumatic brain injuries using proprietary modified mesenchymal stem cells (MSCs) and smart synthetic materials. QS100 is a 3D-printable, implantable MSC-synthetic hydrogel for penetrating brain injuries, while QS200 is an injectable MSC-synthetic hydrogel for concussions. Qrons conducts research in Israel through service agreements with Ariel University and has an ongoing sponsored research agreement with Dartmouth College, serving the healthcare and life sciences sectors, including providers, pharmaceuticals, and biotechnology.

Strategic signal

In February 2025, Qrons completed a reverse merger with First Person Ltd., creating a publicly traded entity focused on cognitive wellness and functional beverages. This strategic move signals a significant pivot for Qrons, expanding its market focus beyond its original neuronal injury treatments into a broader consumer health and wellness space, potentially attracting new investor interest and market opportunities.

Company Intelligence Q&A

What was a significant recent corporate development for Qrons?

In February 2025, Qrons completed a reverse merger with First Person Ltd., forming a new publicly traded company focused on cognitive wellness and functional beverages.

What was the status of Qrons' intellectual property for its QS200 product candidate in March 2023?

In March 2023, Qrons filed the U.S. National Phase of its patent application for therapeutic polypseudorotaxane hydrogels, in furtherance of its QS200 product candidate.

What new research program did Qrons announce in December 2022?

In December 2022, Qrons announced a new pre-clinical research program to test the efficacy of Tellurium Based Compounds, both independently and in combination with its QS200 product candidate, for treating diffused axonal injuries, antibiotic-resistant bacteria, and sepsis.

What was the strategic update provided by Qrons / First Person in July 2025?

In July 2025, Qrons / First Person provided a shareholder update and strategic overview, following their merger earlier in the year.

What new research program did Qrons initiate in July 2023?

In July 2023, Qrons announced the signing of a license agreement term sheet for a new research program to experiment with and commercialize the therapeutic effect of certain Tellurium Based Compounds on antibiotic-resistant bacterial infections, sepsis, and traumatic brain injuries.